Search hospitals > South Carolina > Florence
McLeod Regional Medical Center
Claim this profileFlorence, South Carolina 29506
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Leukemia
120 reported clinical trials
1 medical researcher
Summary
McLeod Regional Medical Center is a medical facility located in Florence, South Carolina. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. McLeod Regional Medical Center is involved with conducting 120 clinical trials across 185 conditions. There are 1 research doctors associated with this hospital, such as Rajesh Bajaj.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
2Cancer
Global LeaderStage IV
HER2 positive
ER positive
Top PIs
Clinical Trials running at McLeod Regional Medical Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Small Cell Lung Cancer
Recurrence
ALK Gene Rearrangement
Peripheral Neuropathy
Multiple Myeloma
Plasma Cell Neoplasms
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at McLeod Regional Medical Center?
McLeod Regional Medical Center is a medical facility located in Florence, South Carolina. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. McLeod Regional Medical Center is involved with conducting 120 clinical trials across 185 conditions. There are 1 research doctors associated with this hospital, such as Rajesh Bajaj.